Social isolation and loneliness can increase the risk for cognitive decline in seniors in assisted living or nursing homes during the COVID-19 pandemic.
There is an inverted U-shaped association between sleep duration and global cognitive decline.
Improvements in lifestyle risk factors for dementia can lead to short-term improvements in cognition among community-dwelling adults experiencing cognitive decline.
The smartphone-based Symbol Digit Modalities Test is a reliable tool for assessment of cognitive function in patients with multiple sclerosis.
Anticholinergic medications are associated with an increased risk for incident mild cognitive impairment and cognitive decline in older adults.
Adults who experience more episodes of moderate/high end-stage renal disease risk have worse performance in cognitive domains in middle age.
Viltepso injection is now available for patients with DMD who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.
Simple coping behaviors may protect against anxiety and depressive symptoms during the COVID-19 pandemic and lockdown.
Compared to routine EEG, continuous EEG increased seizure detection and guided antiseizure treatment, but was not associated with improved outcomes.
The FDA has granted accelerated approval to Viltepso for the treatment of DMD in patients who have a confirmed mutation of the DMD gene.